Since the first description of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), these cells have garnered tremendous interest for their potential use in patient-specific analysis and therapy. Additionally, hiPSC-CMs can be derived from donor cells from patients with specific cardiac disorders, enabling in vitro human disease models for mechanistic study and therapeutic drug assessment. However, a full understanding of their electrophysiological and contractile function is necessary before this potential can be realized. Here, we review this emerging field from a functional perspective, with particular emphasis on beating rate, action potential, ionic currents, multicellular conduction, calcium handling and contraction. We further review extant hiPSC-CM disease models that recapitulate genetic myocardial disease.
Introduction
The successful derivation of human induced pluripotent stem cells (hiPSCs) in 2007 (Takahashi et al., 2007) and their differentiation into functional cardiomyocytes in 2009 (Zhang et al., 2009) has opened new horizons for the use of these cells as disease models and as platforms for drug discovery and toxicity screening [for reviews, see (Davis et al., 2011; Zeevi-Levin et al., 2012) ]. Because cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs) bear the genetic traits of the donors from whom they are obtained, they can serve as new experimental models to study the pathophysiological mechanisms of genetic diseases and to test personalized treatments (Dambrot et al., 2011; Josowitz et al., 2011) . They are potentially also an unlimited source of cardiomyocytes for cardiac regeneration (Nsair and MacLellan, 2011) , although the cost and time required to develop individualized therapy may be prohibitive factors (Freund and Mummery, 2009) .
At present, hiPSCs and human embryonic stem cells (hESCs) are the two types of human pluripotent stem cells that can be differentiated in large numbers into working cardiomyocytes. hiPSC-CMs are particularly attractive for many investigators because they avoid most of the ethical concerns related with hESCs and can be derived in an autologous manner. In studies of cardiac genetic disease, they can potentially be used to supplement or replace animal models that only approximate human physiology or pathophysiology (Hamlin, 2007; McCauley and Wehrens, 2009; Milan and MacRae, 2005) . These hiPSC-CMs can be subjected to detailed analysis of their molecular, pharmacological, electrophysiological and contractile properties [for reviews, see (Kong et al., 2010; Poon et al., 2011) ], yielding valuable mechanistic insight.
However, if these cells are to reach their full potential, they must recapitulate the native physiological function of mature myocardial cells. For example, the utility of hiPSC-CMs from diseased patients lies in their in vitro expression of the functional hallmarks of the disease, so that the basic mechanisms of the disease or effects of disease-specific therapies can be studied. In this article, we review the current state of knowledge regarding the functional properties of hiPSC-CMs. While previous reviews have examined these characteristics largely from a genomic and differentiation perspective (Burridge et al., 2012; Josowitz et al., 2011) , we focus here on fundamental contractile and electrophysiological properties. These are founded on sarcomere and myofilament organization, ion channel expression, calcium cycling proteins, and intercellular coupling. At a functional level, the properties include contractility, intracellular calcium release and uptake, action potentials, and drug responses, which together lead to physiological behavior that includes frequency-dependent changes in contraction and action potential duration, syncytial spread of electrical waves, and excitation-contraction coupling.
In the sections that follow, we summarize the known electrophysiological and contractile properties of hiPSC-CMs and, where applicable, compare them with cardiomyocytes derived from hESCs (hESC-CMs). We also review genetic cardiac diseases that have been modeled by hiPSC-CMs. Because the amount of information is currently rather limited, the extent to which the properties of hiPSC-CMs remain invariant, given the vast range of somatic cells from which hiPSCs can be reprogrammed, remains to be seen. The issue of a well-defined phenotype of the cells is an important consideration for the future usage of hiPSC-CMs and therefore, we address the challenges that exist in the development of hiPSC-CMs as models of physiological and pathophysiological function.
Beating rate

Adrenergic and cholinergic responses
Beating rates in differentiated aggregates (termed embryoid bodies) derived from hiPSCs (hiPSC-EBs), 1 are often investigated as a first line of electrophysiological inquiry. In the adult heart, sinus rhythm is a process tightly regulated by the autonomic nervous system, and many studies have evaluated the response of hiPSCCMs to adrenergic and cholinergic stimulation. Isoproterenol, a badrenergic agonist known to increase sinus rate, increases the spontaneous beating rates in hiPSC-EBs (Fujiwara et al., 2011; Gupta et al., 2010; Mandel et al., 2012; Mehta et al., 2011) and monolayers of hiPSC-CMs (Guo et al., 2011a) in a dose-dependent manner, similar to findings in embryoid bodies from human embryonic stem cells (hESC-EBs) Gupta et al., 2010; Kapucu et al., 2008; Mandel et al., 2012; PekkanenMattila et al., 2009; Reppel et al., 2004; Xu et al., 2006 Xu et al., , 2002 Xu et al., , 2009 Yokoo et al., 2009 ), dissociated hESC-CMs (Pekkanen-Mattila et al., 2009 Xu et al., 2006) and antibiotic selected hESC-CMs (Xu et al., 2009) . Conversely, addition of the b-blocker propranolol prevents the positive chronotropic effect of isoproterenol (Mandel et al., 2012) and, when applied alone, decreases beating rate (Fujiwara et al., 2011) . Carbachol, a cholinergic agonist, also decreases spontaneous beating rates in hiPSC-EBs Mandel et al., 2012) .
Pharmacological responses
In addition to adrenergic and cholinergic regulation, the role of specific ionic channels in regulating spontaneous beating rate has been investigated through the application of various pharmacological agents (see Section 3.2). The L-type calcium channel blocker verapamil was shown to decrease spontaneous beating rate of individual hiPSC-EBs in a dose-dependent manner and cease spontaneous beating at high concentrations (Mehta et al., 2011; Yokoo et al., 2009 ), similar to findings in hESC-EBs Yokoo et al., 2009) .
Conversely, the L-type calcium channel agonist Bay K 8644 has been shown to increase spontaneous beating rates in hiPSC-CMs (Mehta et al., 2011) . Interestingly, the L-type calcium channel blocker nifedipine also increased beating rates in hiPSC-CMs (Guo et al., 2011a (Guo et al., , 2011b . However, the nifedipine experiments were conducted using cryopreserved hiPSC-CMs, which may have different electrophysiological properties than those of fresh cells, given that cryopreservation has been shown to increase spontaneous beating rates in hESC-CMs (Kim et al., 2011b) .
Blockade of the pacemaker current (I f ) with ZD 7288 (Guo et al., 2011a) , potassium channels with amiodarone (Yokoo et al., 2009) , or the rapid-delayed rectifier potassium current (I Kr ) with E-4031 (Guo et al., 2011a; Liang et al., 2010) all resulted in decreased beating rates in hiPSC-CMs. The responses to sodium channel (I Na ) blockers are more complex: TTX decreased spontaneous beating rate (Guo et al., 2011a) while procainamide, mexiletine and flecainide had no effect (Yokoo et al., 2009) , perhaps due to differences in the specific mechanisms underlying the channel blockage or to multiple drug targets.
In one application of the cells, hiPSC-CMs were used for pharmacological screening and assessed for irregular spontaneous beating patterns reminiscent of arrhythmias (Guo et al., 2011a) . Several cardioactive drugs known to block I Kr , prolong the QT interval, or induce Torsades de Pointes (TdP, a life-threatening tachyarrhythmia characterized by an irregular rhythm) e including E-4031, RO5657, astemizole, cisapride, dofetilide, erythromycin, flecainide, quinidine, sotalol, terfenadine, and thioridazine e were applied to hiPSC-CMs and shown to induce dose-and time-dependent irregular spontaneous beating. In another study, hiPSC-CMs served as a model for studying cardiotoxicity and electrophysiological alteration caused by an oral drug, sunitinib (Cohen et al., 2011) .
Electrophysiology
Action potentials
Microelectrode and patch clamp recordings
The properties of the cardiac action potential (AP) enable proper cardiac electrical and contractile function. Slow, regular depolarization from rest is necessary in the nodal regions of the heart as the basis for automaticity, while fast upstroke velocities and long action potential durations (APDs) allow fast propagation and calcium influx for contraction in the ventricles. An understanding of hiPSC-CM AP properties is, therefore, critical for an accurate assessment of the functional maturity of the cells. APs have been recorded from single hiPSC-CMs (Burridge et al., 2011; Fujiwara et al., 2011; Haase et al., 2009; Lee et al., 2011; Ma et al., 2011; Novak et al., 2010; Ren et al., 2011; Zhang et al., 2009) and in clusters of hiPSC-CMs (Burridge et al., 2011; Fujiwara et al., 2011; Haase et al., 2009; Lee et al., 2011; Ma et al., 2011; Novak et al., 2010; Ren et al., 2011; Zhang et al., 2009) . In agreement with the hESC-CM literature, three AP phenotypes (nodal-, atrial-, or ventricular-like) (Fujiwara et al., 2011; Haase et al., 2009; Lee et al., 2011; Ma et al., 2011; Zhang et al., 2009 ) have generally been identified ( Table 1 ). The percentages of each phenotype clearly depend on the selection criteria, which are not always well-defined, although in some cases quantitative measures have been used, such as the ratio of APD at different percentages of repolarization .
A general finding is that a single AP phenotype predominates over others within a single EB (Zhang et al., 2009) . This is in agreement with similar studies in hESC-CMs (He et al., 2003; Magyar et al., 2000) . Across different cell lines, the percentages of electrophysiological phenotypes vary, ranging from 38% to 54% for the ventricular phenotype when measured in isolated cells Ma et al., 2011) to 70e74% in EBs (Zhang et al., 2009) . These percentages are similar to those in hESC-CMs, and to optical mapping measurements from our group that found predominantly ventricular-like potentials for both hESC-CMs and hiPSC-CMs (Burridge et al., 2011) .
Studies in both hiPSC-CMs (Fujiwara et al., 2011; Haase et al., 2009 ) and hiPSC-EBs (Zhang et al., 2009 ) reported ventricular-like action potentials with maximum diastolic potential (MDP) values near À60 mV. However, a more recent report in a blasticidinenriched population of single cells reported a value of À75 mV , closer to the À87 mV resting potential of adult ventricular cells (Drouin et al., 1995) . hiPSC-CM ventricular action potential amplitude (APA) in these studies ranged from 85 to 105 mV. Maximum upstroke velocity (dV/dt max ) and APD at 90% repolarization had ranges of 10e40 V/s and 300e400 ms respectively (Haase et al., 2009; Ma et al., 2011; Zhang et al., 2009 . There was no significant difference in differentiation time among these studies to account for the wide range of values, but each used a different cell source (fetal or newborn fibroblasts or cord blood endothelial cells) and, sometimes, a cardiomyocyte enrichment process. As a further illustration of hiPSC-CM functionality, APD decreases with increasing stimulation rates (1e3 Hz) (Zhang et al., 2009) . In general the AP properties of hiPSC-CMs are similar to those of the more extensively studied hESC-CMs and are those of immature cardiac cells (low resting potential, slow upstroke velocity, and diastolic depolarization).
Pharmacologically, application of TTX to isolated cells delayed AP upstroke and decreased dV/dt max . Nifedipine decreased isolated cell APDs at 10, 50, and 90% repolarization , while E-4031 increased APD in a dose-dependent manner (Fujiwara et al., 2011; Ma et al., 2011; Moretti et al., 2010) . Chromanol 293B, a blocker of the slow delayed rectifier current I Ks , did not cause significant APD changes .
Field potentials
Extracellular field potentials measured by microelectrode arrays (MEAs) can serve as a surrogate for AP measurements in multicellular preparations (Halbach et al., 2003) . The amplitude of the first negative peak of the field potential has been used as a measure of dV/dt max , and was found to decrease with TTX (Mehta et al., 2011) . Field potential duration (FPD) directly correlates with APD in cardiomyocytes and the QT interval of an electrocardiogram, and its response to various ion channel blockers has been measured in hiPSC-EBs or monolayers of hiPSC-CMs. Consistently, FPD is prolonged by E-4031 (Braam et al., 2010; Caspi et al., 2009; Fujiwara et al., 2011; Mehta et al., 2011) and shortened by verapamil (Braam et al., 2010; Liang et al., 2010; Mehta et al., 2011) and nifedipine (Braam et al., 2010; Guo et al., 2011b) .
Optical mapping
Optical mapping is a technique in which stem cell-derived cardiomyocytes can be stained with a fluorescent dye and, upon illumination, emit a fluorescent signal related to the activity of the cell (Weinberg et al., 2010) . We recently used optical mapping to measure the transmembrane voltage and intracellular calcium levels of cell clusters mechanically dissected from hiPSC-EBs derived from cord blood cells (Burridge et al., 2011) . Optical recordings of transmembrane potential (V m ) or intracellular calcium (Ca i ) were recorded using an electron multiplying charged coupled device (EMCCD) camera at 490 frames per second. In V m recordings, we found that electrical waves propagated across the hiPSC-EB, demonstrating a functional syncytium (Fig. 1A (aec) ). Additionally, in Ca i recordings, intracellular calcium transients were present in the hiPSC-EB, which also propagated across the EB as calcium waves (Fig. 1B) . In a study from another group, APDs of hiPSC-EBs were found to be predominantly ventricular-like, prolonged by procainamide (sodium and potassium channel blocker) and shortened by verapamil (Ren et al., 2011) .
Ionic currents
Recent studies have characterized the biophysical properties of the ionic currents I Na , I CaL , I K1 , I to , I Kr , I Ks , and I f in hiPSC-CMs. Gene expression data of the corresponding ion channels are summarized in Table 2 , although in no case were data in this table evaluated for a specific electrophysiological phenotype. These data demonstrate that the major currents responsible for the AP in native cardiomyocytes are genetically expressed and that their gene expression increases with differentiation time.
The presence and upregulation of these cardiac ion channel genes has led to investigations of the functional presence of their associated currents. Each of the currents in Table 2 has been identified functionally in hiPSC-CMs by voltage-and current-clamp experiments that are summarized below. However, the currents have not yet been studied for specific AP phenotypes. In many cases direct comparison of currents is confounded by different voltage protocols or experimental conditions between studies.
Voltage clamp separation of the fast sodium current demonstrated that I Na has a maximal value of À216 pA/pF at À20 mV , in close agreement with previous hESC-CM measurements (Satin et al., 2004) . For comparison, I Na of adult human ventricular cardiomyocytes can be estimated from the O'Hara computational model (O'Hara et al., 2011) to have a peak amplitude of À196 pA/pF at À17 mV under physiological conditions. Peak L-type calcium current, I CaL , of À17 pA/pF at 0 mV (with 5 mM extracellular Ca 2þ ) has been reported via voltage clamp separation and is about four times larger than that reported in hESC-CMs (with 1.8 mM extracellular Ca 2þ ) (Sartiani et al., 2007) . The same hiPSC-CM study also noted an absence of T-type calcium currents. In human ventricular cells from children, peak I CaL is approximately À5.8 pA/pF at þ10 mV (Pelzmann et al.,1998) . A recent study showed that, in comparison to native guinea pig ventricular myocytes, hiPSC-CMs maintained similar kinetic responses to antagonists, but different responses to activators (Kang et al., 2012) .
The inward rectifier potassium current, I K1 , has not generally been found in hiPSC-CMs, similar to studies in hESC-CMs (Fu et al., 2010 (Fu et al., , 2011 He et al., 2003; Satin et al., 2004) . However, one study reported I K1 as a Ba 2þ -sensitive current with an amplitude of À2.3 pA/pF at À123 mV , less than that in adult ventricular cells (À10 pA/pF at À90 mV) (Wang et al., 1998) . This is near the value reported in hESC-CMs that were differentiated for 50e110 days (Sartiani et al., 2007) . The same study also reported an MDP value of À75 mV, the most negative to date in hiPSC-CMs, suggesting that I K1 is functionally active. The hiPSC-CMs used in that study were highly purified by exploiting blasticidin resistance under the control of the a-myosin heavy chain promoter, which may contribute to a more mature phenotype. The transient outward current, I to , was measured by voltage clamp separation and has a reported density of 2.5 pA/pF at 60 mV . This value is lower than that reported in hESC-CMs (6 pA/pF at 50 mV) (Fu et al., 2011) , but is within the range of values reported in adult ventricular cells (2.3 AE 0.3 to 7.9 AE 0.7 pA/pF at 60 mV for subepicardial and subendocardial cells, respectively) (Wettwer et al., 1994) .
The rapid delayed rectifier potassium current, I Kr , has been measured as an E-4031-sensitive current with a maximal current of 0.4 pA/pF at approximately À10 mV . This magnitude agrees closely with that in hESC-CMs, but it occurs at a more negative voltage (Fu et al., 2011; Li et al., 1996; Wang et al., 2011) . In adult ventricular cardiomoycytes, I Kr can be determined from the O'Hara model to have a magnitude of 0.82 pA/pF at þ7 mV under physiological conditions.
The slow delayed rectifier potassium current, I Ks , is functionally expressed in single hiPSC-CMs Moretti et al., 2010; Wang et al., 2011) , as it is in hESC-CMs (Wang et al., 2011) . It was measured as a chromanol 293B-sensitive current and, when present, had a relatively small magnitude (0.31 pA/pF at 40 mV in 5 of 16 cardiomyocytes studied) . In adult ventricular cardiomyocytes, I Ks can be determined from the O'Hara model to have a magnitude of 0.58 pA/pF at þ40 mV under physiological conditions.
The pacemaker current, I f , has been measured in single cells via voltage clamp separation and has a value of À4.1AE0.3 pA/pF at À120 mV . This is smaller in magnitude than the value reported in adult sinoatrial node cells (À7 pA/pF at À120 mV) (Verkerk et al., 2007) . The I f blockers ZD7288 and CsCl each significantly decreased I f current density in hiPSC-CMs.
Cellecell coupling
Cellecell coupling provides a mechanism for direct electrical connections between neighboring cardiomyocytes within an hiPSC-EB. Synchronous beating across the hiPSC-EB provides visual evidence of cellecell coupling, although it may be difficult to distinguish whether it is the result of electrical synchrony of activation or the mechanical pulling of one cell on adjacent cells. The following studies have provided evidence for direct electrical cellecell coupling of cardiomyocytes within hiPSC-EBs.
Gap junctions
The presence of gap junctions among hiPSC-CMs has been demonstrated in several studies by immunofluorescence imaging (Haase et al., 2009; Martinez-Fernandez et al., 2009; Zwi et al., 2009 ). However, one study using electron microscopy was unable to find gap junctions in hiPSC-EBs after 38 days of differentiation (Gherghiceanu et al., 2011) .
Conduction
Apart from the presence of junctional coupling proteins, a functional syncytium is ultimately demonstrated by the occurrence of electrical conduction. One study of spontaneously beating hiPSC-EBs reported conduction velocity measurements of 1e2 cm/s at physiological temperatures (Mehta et al., 2011) . hiPSC-EBs respond to a range of cardioactive compounds. For example, TTX slows conduction in a dose-dependent manner (Mehta et al., 2011) , suggesting a Na þ current-driven conduction similar to that in adult myocardium.
In optical mapping experiments from our group (Burridge et al., 2011) , conduction velocities in EBs were on average w 1 cm/s and increased with the addition of isoproterenol (Fig. 1A d) .
Contractility
Contraction and force generation
Immunofluorescence studies have demonstrated the presence of organized structural and contractile proteins forming sarcomere patterns in hiPSC-CMs (Fig. 2) (Burridge et al., 2011; Fujiwara et al., 2011; Gai et al., 2009; Germanguz et al., 2011; Gupta et al., 2010; Haase et al., 2009; Itzhaki et al., 2011b; Lee et al., 2011; Novak et al., 2010; Ren et al., 2011; Tulloch et al., 2011; Yokoo et al., 2009; Zhang et al., 2009; Zwi et al., 2009 ), similar to previous findings in hESC-CMs. Studies have also shown that hiPSC-CMs contract in response to electrical stimulation (Germanguz et al., 2011; Novak et al., 2010) . One study showed that block of L-type calcium channels decreased the amplitude of contraction in a dose-dependent Dermal 201B7 KCNJ2 Kir2.1 Present but no maturation effects were reported. (Yokoo et al., 2009) manner, like that seen in hESC-CMs (Yokoo et al., 2009 ). Similar to observations in hESC-CMs, the addition of isoproterenol increased the amplitude and rate of contraction in hiPSC-CMs (Germanguz et al., 2011; Novak et al., 2010; Yokoo et al., 2009) , with a greater increase in contraction from isoproterenol observed in later stage (18e70 day) cells compared with earlier stage (10e15 day) cells (Germanguz et al., 2011) . A negative forceefrequency relation (rate-staircase) of contraction was measured in small aggregates of hiPSC-CMs (Germanguz et al., 2011) , similar to that observed for hESC-CMs in the same study but unlike the positive forceefrequency relation characteristic of native myocardium (Endoh, 2004) . However, the same study also showed weak post-rest potentiation of contraction, suggesting some accumulation of Ca 2þ stores.
Furthermore, ryanodine decreased peak contraction amplitude and maximum rates of contraction and relaxation of hiPSC-EBs, but had no effect on hESC-EBs. These findings suggest functional but immature calcium cycling in hiPSC-CMs.
Calcium cycling
Recently, much effort has gone into the characterization of calcium cycling in hiPSC-CMs and, in some studies, comparisons with hESC-CMs. Expression of key calcium cycling proteins or their gene products has been demonstrated (Table 3) : Ca v 1.2, RyR2, SERCA2a, and IP3R2, as well as of the regulatory proteins calsequestrin (CSQ) and phospholamban (PLN) (Itzhaki et al., 2011b) . However, in no case were these expression data evaluated for a specific electrophysiological pheonotype. One study compared cardiomyocytes derived from two hiPSC cell lines with those from two hESC cell lines, and expression of RyR2 and SERCA2a was significantly lower in the hiPSC-CMs . In another study, protein expression of RyR and CSQ was obtained in hiPSCCMs (Germanguz et al., 2011) .
Functional calcium transients are present in hiPSC-CMs and can be used to assess calcium release and uptake from the sarcoplasmic reticulum (SR), although in no case were these SR properties evaluated for a specific electrophysiological phenotype (Table 4) . One study found that calcium transients could be abolished by blocking calcium influx through the L-type calcium channel, calcium release via the RyR release channel, or calcium uptake via the SERCA pump (Itzhaki et al., 2011b) . Comparative studies of hiPSC-CMs with hESC-CMs revealed smaller calcium transient amplitudes and slower upstroke and decay rates in hiPSC-CMs, suggesting less mature calcium cycling in hiPSC-CMs . Partial block of RyR release reduced the calcium transient amplitude and slowed the upstroke rate in hiPSC-CMs, but to a lesser extent than in hESC-CMs. This finding indicates that calcium cycling is not fully operational in hiPSC-CMs, contrary to observations in hESC-CMs and contradicting the contraction experiments reported in Section 4.1.
Addition of the b-adrenergic agonist isoproterenol, known to increase L-type calcium channel current and SR calcium release (Eisner et al., 2009) , increased the amplitude of calcium transients (Novak et al., 2010; Ren et al., 2011) .
As with hESC-CMs, hiPSC-CMs exhibit SR calcium release sensitivity to large doses of caffeine, revealing the presence of functional SR calcium stores (Germanguz et al., 2011; Gupta et al., 2010; Itzhaki et al., 2011b; Lee et al., 2011) . One study showed reduced calcium release and slower release rate following caffeine in hiPSC-CMs compared with hESC-CMs, along with U-shaped calcium waves attributable to the absence of T-tubules in both hESC-CMs and hiPSC-CMs . The delay was greater for hiPSC-CMs, consistent with reduced expression of triadin . In line with the latter findings, a study using electron microscopy failed to find T-tubules in hiPSC-CMs (Gherghiceanu et al., 2011) , although that study also found poorly developed SR in contrast with the prior mentioned studies.
Additionally, SR calcium stores were recently shown to regulate the spontaneous beating of hiPSC-CMs. Blocking either RyR or IP3R calcium release decreased the spontaneous beating rate (Itzhaki et al., 2011b) , similar to results in hESC-CMs (Kim et al., 2010a) and consistent with the proposed "calcium-clock" mechanism for spontaneous sinus rhythm (Maltsev and Lakatta, 2007) .
Disease models
In order to provide mechanistic insights into cardiac genetic diseases or serve as patient-specific cardiac drug testing platforms, hiPSC-CMs models must faithfully recapitulate the disease phenotype and pathoelectrophysiology. Unlike hESC-CM-based disease models which can only be created for known mutations that are introduced into the cells (Maury et al., 2012) , hiPSC-CMs can be produced from patient-derived somatic cells and will retain the genetic abnormalities associated with the patient's condition. Several cardiac disease models have been established with hiPSCCMs and demonstrate the ability to recapitulate the cellular pathogenic hallmarks of the diseases. In 90% of cases, it is caused by a missense mutation in the PTPN11 gene encoding the protein tyrosine phosphatase SHP2, which has the capacity to enhance activation of RAS-MAPK signaling (Digilio et al., 2002; Edouard et al., 2007) . Left ventricular hypertrophy is the most common cardiac anomaly (Limongelli et al., 2007) .
LEOPARD syndrome
Dermal fibroblasts were reprogrammed from LEOPARD syndrome patients having heterozygous T468M substitution mutations in PTPN11 (Carvajal-Vergara et al., 2010) and then differentiated into cardiomyocytes. The hiPSC-CMs that were generated exhibited increased cell size and sarcomeric organization, suggestive of the cardiac hypertrophic response, as well as aberrant RAS-MAPK signaling. One limitation of the model is that cardiac differentiation from hiPSCs was performed by standard EB culture, resulting in a heterogeneous population of cells. As noted by the study investigators, in the absence of a purified cardiomyocyte population, protein synthesis rates and fetal gene program reactivation could not be used to assess cardiomyocyte hypertrophy.
Long QT syndrome
Long QT syndrome (LQTS) is a congenital cardiovascular disorder characterized by prolongation of the QT interval and syncopal episodes due to polymorphic ventricular tachycardia that may lead to cardiac arrest and sudden cardiac death (Crotti et al., 2008) . The syndrome can be caused by a variety of mutations in genes encoding cardiac ion channels, with the most common types, LQT1 and LQT2, occurring from mutations in KCNQ1 and KCNH2. These genes encode the alpha subunits of potassium channels that conduct I Ks and I Kr , respectively (Josowitz et al., 2011; Marban, 2002) . Studying LQTS is of interest because of its prevalence [estimated at 1 in 2500 live (Germanguz et al., 2011) Note: a Level indicates whether contractility studies were performed in isolated cells (indicated by 'Single') or hEBs. births (Crotti et al., 2008) ] and because measures such as AP prolongation can be used to screen potential therapeutics. hiPSCs were generated by reprogramming dermal fibroblasts from patients with a heterozygous R190Q missense mutation in the KCNQ1 gene (Moretti et al., 2010) . The LQT1 hiPSC-CMs could be classified as ventricular-, atrial-, or nodal-like based on AP phenotype (see Section 3.1.1) and specific myocyte-lineage markers that distinguish between these phenotypes. Ventricular-and atrial-like hiPSCCMs exhibited longer APs, slower repolarization, and decreased APD shortening in response to higher pacing frequencies (decreased APD restitution slope) compared with ventricular-and atrial-like hiPSCCMs from healthy control subjects. Immunocytochemical studies of KCNQ1 suggested a trafficking defect in these cells, while whole-cell patch clamping indicated a 75% decrease in I Ks conductance along with altered I Ks activation and inactivation. In spontaneously beating LQT1 hiPSC-CMs, adrenergic stimulation induced early afterdepolarizations (EADs), affecting approximately 9% of beats.
Pretreatment with a b-blocker decreased the effect of adrenergic stimulation, resulting in EADs that affected about 2% of beats.
hiPSC-CMs have been derived from LQT2 patients with a A614V (Itzhaki et al., 2011a) , G1681A (Matsa et al., 2011) , or R176W (Lahti et al., 2011) mutation in the KCNH2 gene. In all three models, atrial-and ventricular-like LQT2 hiPSC-CMs had prolonged APDs compared with control hiPSC-CMs derived from healthy human (Itzhaki et al., 2011a; Lahti et al., 2011) or from hESC-derived fibroblasts (Matsa et al., 2011) . However, in the case of the R176W mutant cells, this prolongation was only statistically significant for ventricular-like cells, and nodal-like APDs were not observed (Lahti et al., 2011) . With the A614V and G1681A mutants, APDs in nodallike hiPSC-CMs were not significantly prolonged in the LQT2 model compared with controls (Itzhaki et al., 2011a; Matsa et al., 2011) . Multicellular clusters of LQT2 hiPSC-CMs, in the form of hEBs (Itzhaki et al., 2011a; Matsa et al., 2011) or spontaneously beating cardiomyocyte aggregates excised from END-2 co-culture (Lahti et al., 2011) , exhibited prolonged FPD compared with healthy hiPSC-CM controls (Itzhaki et al., 2011a; Lahti et al., 2011; Matsa et al., 2011) . The relative ventricular:atrial:nodal-like composition of these clusters was not specified. In the A614V model, hiPSC-CMs in hEBs developed both single and sustained EADs, as well as ectopic activity (Itzhaki et al., 2011a) . EADs were also elicited in the G1681A model with the application of adrenergic stimulation, along with a greater reduction in single-cell APD relative to controls (Matsa et al., 2011) . Sotalol elicited EADs in the R176W model at the highest concentrations tested (Lahti et al., 2011) . In all of the models, blocking I Kr through the addition of E4031 caused APD prolongation and evoked new or increased the number of existing EADs. I Kr was found to be reduced in the A614V and R176W models but was not measured in the G1681A model (Itzhaki et al., 2011a; Lahti et al., 2011) . Potassium channel openers (Itzhaki et al., 2011a; Matsa et al., 2011) or an L-type Ca channel blocker (Itzhaki et al., 2011a) decreased APD in the A614V and G1681A models. In G1681A hiPSCCMs, treatment with potassium channel activators in combination with adrenergic stimulation evoked EADs (Matsa et al., 2011) .
Timothy syndrome
Timothy syndrome is a multisystem disorder that results in syncope and severe cardiac arrhythmias that can lead to sudden cardiac death (Splawski et al., 2005) . It is caused by a mutation of the CACNA1C gene encoding Ca V 1.2, the alpha 1C subunit of the Ltype Ca channel. This results in maintained inward Ca 2þ currents due to loss of voltage-dependent Ca 2þ channel inactivation (Splawski et al., 2004) . hiPSC-CMs have been derived from fibroblasts of Timothy syndrome patients with a G406R mutation in exon 8a of the CACNA1C gene (Yazawa et al., 2011) . Action potentials of ventricular Timothy syndrome hiPSC-CMs were three times longer than those of control hiPSC-CMs from healthy individuals, and voltage-dependent inactivation of I CaL was reduced compared with controls. These cells also exhibited a large number of delayed after depolarization-like events. Additionally, the intracellular Ca 2þ transients were irregular in timing and amplitude, exhibiting larger and more prolonged elevations compared with controls, consistent with delayed Ca V 1.2 inactivation. Application of the cyclindependent kinase inhibitor roscovitine reduced irregularities in the timing and amplitude of Ca 2þ transients, reduced APD, and decreased the frequency of abnormal depolarizing events.
Catecholaminergic polymorphic ventricular tachycardia
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an arrhythmogenic disorder that can result in sudden cardiac death and is caused by mutations in the calsequestrin (CASQ2) gene or in the RyR2 gene encoding the cardiac isoform of the ryanodine receptor (di Barletta et al., 2006) . hiPSC-CMs have been derived from dermal fibroblasts of CPVT patients with a D307H mutation of the CASQ2 gene and from a patient with a S4061L mutation in the RyR2 gene (Jung et al., 2012) . Treatment of the mutant CASQ2 hiPSC-CMs with isoproterenol induced aftercontractions and triggered activity concurrent with a rise in resting tension level, as well as delayed afterdepolarizations and late diastolic oscillations . Unlike control hiPSCCMs, contraction amplitude, maximal contraction rate, and relaxation rate were all unaffected by isoproterenol in CPVT hiPSC-CMs. APD at 50% repolarization was nearly twice as long in CPVT cells, but other parameters (APA, dV/dt max ) were similar. Myofibrillar structure was less organized, and fewer caveolae were found in CPVT versus control hiPSC-CMs .
In the mutant RyR2 hiPSC-CMs, delayed afterdepolarizations and triggered activity were also observed in a majority of ventricularand atrial-like hiPSC-CMs during pacing (Jung et al., 2012 properties, Ca 2þ handling during catecholaminergic challenge, delayed afterdepolarizations, and triggered activity, was rescued by the application of the drug dantrolene.
6. Future challenges 6.1. Deriving large-scale amounts of clinically useful cardiomyocytes for regenerative medicine
Although many published studies have demonstrated the ability of pluripotent stem cells to differentiate into cardiomyocytes (Burridge et al., 2007; Gai et al., 2009; Habib et al., 2008; Laflamme et al., 2007; Mummery et al., 2003; Zhang et al., 2009; Zwi et al., 2009) , the current inefficiency of these systems makes the massive scale of cardiomyocytes needed to replace the cells from a single patient's myocardial infarction (MI) impractical. For example, it has been estimated that one billion cardiomyocytes are lost in a typical MI, and over one hundred 10 cm dishes of cells would be required to replace these infarcted cells. This task requires a substantial investment in increasing the efficiency and scalability of obtaining hiPSC-CMs, which is significantly lower than those of hESCs for which current hESC differentiation protocols typically produce small percentages of beating hEBs. The second major limitation involves the technical caveats (and safety risks) of deriving hiPSCs with viral vectors. Despite overall silencing of integrated retroviral and lentivector promoters during iPSC generation, low levels of viral transgenes or reactivated vector promoters result in incompletely reprogrammed states that promote insertional mutagenesis, or even malignant transformation (Miura et al., 2009; Nakagawa et al., 2008) . Alternative approaches for generating hiPSCs are needed that reduce these risks by avoiding either the use of stably integrating sequences or potentially mutagenic chromatin-modifying molecules to enhance reprogramming (Burridge et al., 2011; Jia et al., 2010; Okita et al., 2008; Stadtfeld et al., 2008; Warren et al., 2010; Yu et al., 2009; Zhou et al., 2009) . Much investment in this high priority area of research is still needed.
Developing faithful hiPSC models of cardiac disease
The use of hiPSCs for applications in disease modeling is now advancing markedly. However, despite the rapid pace of improvement in cardiac differentiation methods and development of new hiPSC lines harboring cardiac disease phenotypes, significant challenges still remain. For example, there are several important aspects relating to the generation of hiPSCs that impact the faithful recapitulation of the electrophysiological cardiac disease phenotype. These include the developmental maturity and the retention of somatic epigenetic memory of hiPSCs. Thus far, the cardiomyocytes that have been generated from hiPSCs display an immature electrophysiological and contractile phenotype (see Sections 3.1.1, 4.1, and 4.2). These cardiomyocytes also displayed spontaneous contractions, embryonic cardiac gene expression profiles, and fetal type ion channels. It is unclear at this time if these developmentally immature phenotypes will pose a limitation for downstream drug testing and disease modeling applications. Furthermore, the generation of immature cardiomyocytes with automaticity will likely pose a challenge for ultimate application in regenerative medicine. It is not clear if these cardiomyocytes will engraft robustly in damaged adult myocardium environment with a vastly incongruent physiological status. On the other hand, there is also the possibility that developmentally immature cardiomyocytes may alternatively display an augmented long term survival in an adult environment, since rat fetal cardiomyocytes engraft more potently in rat adult myocardium (Reinecke et al., 1999) . Approaches will be needed to mature fetal-like hiPSC-CMs further, much like those that are being developed for hESC-CMs (Magyar et al., 2000) , and the detailed electrophysiologic characterization using the methods we have reviewed herein will be vital in solving this critical caveat.
An important caveat, that our group has specifically invested effort into solving, is the obstacle of interline variability in cardiac differentiation that exists in hiPSC and hESC lines (Burridge et al., 2011) . Although various hESC lines have been documented to have a greater propensity for cardiac differentiation (Burridge et al., 2007; Osafune et al., 2008; Pal et al., 2009; Pekkanen-Mattila et al., 2009) , this variability appears to be even more pronounced for hiPSCs (Narsinh et al., 2011) . The various factors that likely contribute to this efficiency in cardiac differentiation include the protocol used for cardiac induction, the somatic source used for reprogramming (e.g. fibroblasts vs. blood cells) (Kim et al., 2010b (Kim et al., , 2012 Polo et al., 2010) , the expression of endogenous mesoderm-inducing factors in various pluripotent lines, and the retention of somatic memory of the reprogrammed donor cell, which may inherently prevent differentiation across lineages (Kim et al., 2010b (Kim et al., , 2012 ) (for example from fibroblast to neural or cardiac lineages). Retention of somatic epigenetic memory was initially thought to be restricted to incompletely reprogrammed, low passage hiPSCs. However, further work has revealed that even after prolonged passages, there are quantitative losses in differentiation potential of hiPSCs in comparison to hESCs (Kim et al., 2011a; Polo et al., 2010) . More refined cardiac differentiation protocols (Burridge et al., 2011) , as well as improved methods of reprogramming that produce hiPSCs with minimal epigenetic memory may overcome these obstacles in the near future.
Developing hiPSC models for drug discovery
The efficient in vitro production of human cardiomyocytes from induced pluripotent stem cells also opens unique opportunities for deriving genetically-defined cells for drug discovery applications (Yokoo et al., 2009 ); for reviews, see (Davis et al., 2011; Zeevi-Levin et al., 2012) . However, discovery, development, and safety testing of novel drugs is a long, arduous and expensive process that is complicated by expensive and unreliable methods for accurately modeling human cardiac electrophysiology. The pharmaceutical industry currently invests w$1.5 billion to take a candidate drug from primary screen to market, and many drugs are withdrawn due to side effects associated with electrophysiological alterations. For example, the anti-inflammatory drug Vioxx and the gastrointestinal prokinetic drug Cisapride were both withdrawn following unanticipated arrhythmogenic toxicities (Fermini and Fossa, 2003) . Off-target cardiac toxicity is also the most common cause of regulatory delays in approvals or market withdrawals of new pharmaceuticals. Current barriers that impede drug discovery and development include: 1) the use of non-translatable nonhuman animal models for assessment of off-target toxicity; 2) the performance of early compound safety screening studies with quantities too small for scale-up to animal models; 3) the small scale of human clinical trials (usually 20e50 patients) that do not include critically relevant genetic backgrounds.
The use of hiPSC-derived cardiomyocytes provides the potential to reduce the burden of each of these factors, and therefore reduce the time and cost of bringing new drugs to market. Within the limitations of immaturity as outlined above, cardiomyocytes display relatively normal cardiac molecular, structural and functional characteristics, survive under cell culture conditions for extended periods, and can be grown in controllable environmental conditions. Thus, large-scale generation of cardiomyocytes from normal or heart disease-affected hiPSCs holds the potential to serve as a human-based model for both drug development and cardiotoxicity screening and would provide the pharmaceutical industry with an invaluable tool for pre-clinical screening of candidate anti-arrhythmic, anti-heart failure, and other medicines for secondary cardiac toxicities (e.g. chemotherapeutics; (Farokhpour et al., 2009) ).
The effects of drugs on pluripotent stem cell-derived cardiomyocytes could potentially be assayed using simple 'number of beating hEB' assays (Burridge et al., 2011; Farokhpour et al., 2009) or more detailed studies using current clamp (Chaudhary et al., 2006) , patch-clamp, laser capture microscopy (Chaudhary et al., 2006) , or MEAs (Tanaka et al., 2009 ). Both automated robotic high-throughput patch-clamp systems and MEA systems enabling high throughput screening of 96 or even 384 compounds simultaneously are already commercially available. These systems enable the measurement of the surface electrogenic activities of cell clusters and allow stable, long-duration recordings that are necessary to evaluate the relationships between dose-dependency and the inductive side-effects of new drugs. Since the washing out of drugs can lead to the recovery of the field potential waveform to the baseline observed before the drug application, such systems can test the reproducibility of pharmacological effects of multiple drugs on the same sample. Ultimately, the use of hiPSC-CMs will allow the possibility of drug testing on a panel of cell lines that might more closely reflect the genetic diversity of a population, such as is currently performed using murine ESCs (McNeish, 2004) . Genetic conditions that affect the heart such as familial cardiomyopathy, familial lethal arrythmias and congenital heart diseases, as reviewed above, can further be studied with appropriate disease-harboring hiPSCs.
Conclusion
Despite their relatively recent discovery, the electrophysiological and contractile function of hiPSC-CMs has been the subject of significant research investigation. To date, their beating rates, action potentials, ionic currents, calcium cycling, and contractility are similar to the more extensively studied hESC-CMs, but are still immature relative to adult hearts. Many factors can hinder the attainment of a well-defined myocyte phenotype, including variability introduced from different culture conditions, cell sources, differentiation times, and the retention of somatic epigenetic memory. Thus far, the cardiomyocytes that have been generated from hiPSCs have displayed an immature electrophysiological phenotype that is akin to fetal cardiac tissue. These cardiomyocytes display spontaneous automatic contractions, embryonic cardiac gene expression profiles, and fetal-like ion channel expression and calcium cycling. It is unclear at this time if these developmentally immature phenotypes will pose a limitation for downstream drug testing applications. Furthermore, the generation of immature cardiomyocytes with automaticity will likely pose a challenge for ultimate application in regenerative medicine. It is also not clear if these cardiomyocytes will engraft robustly and seamlessly in a damaged adult myocardium environment with a vastly incongruent physiological status. Approaches are needed to maturate the fetal-like hiPSC-CMs, and the detailed electrophysiologic and contractile characterization reviewed herein will be vital in solving this critical caveat.
The cardiac genetic disease models tested so far seem promising for mechanistic studies and future drug discovery, but it remains to be seen whether the level of developmental maturity and suppression of somatic epigenetic memory of hiPSC-CMs is sufficient for the cells to recapitulate all of the critical disease characteristics and to respond to pharmacological agents in a manner reflective of the genetic traits and function of cardiomyocytes in the patient population.
Editors' note
Please see also related communications in this issue by Blazeski et al. (2012) and Morris et al. (2012) .
